Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
Authors
Dai‐Hong Liu (ORCID: https://orcid.org/0000-0003-3334-9113)
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
Dai‐Hong Liu, Hui-Sheng Zhou, Xiaoning Gao, Yuqing Li et al.
Journal
Frontiers in Immunology
Topics
Cancer Immunotherapy and Biomarkers
article
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia
Dai‐Hong Liu, Hui-Sheng Zhou, Xiaoning Gao, Yuqing Li, An Wang, Jun Wang, Xuan Zheng, Lei Xu, Yizhi Wang, Yong-Feng Su, Kai-Li Min, Chunji Gao, Ya-Lei Hu
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in ImmunologyVol. 16
Institutions
Chinese PLA General Hospital (CN)
Funders
National Natural Science Foundation of China, General Hospital of People’s Liberation Army